The Drug Development Letter

The Drug Development Letter

Share this post

The Drug Development Letter
The Drug Development Letter
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301.
Copy link
Facebook
Email
Notes
More

Tislelizumab, a novel anti-PD1 in…

Timothée Olivier
Sep 8, 2024
17

Share this post

The Drug Development Letter
The Drug Development Letter
Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301.
Copy link
Facebook
Email
Notes
More
1

Quality-of-life data should be interpreted with extra caution when censoring rates are high.

Read →
Comments
User's avatar
© 2025 Vinay Prasad
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More